Drugs / ES502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07649928 | May 2026 → Dec 2028 expected | malignant pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ES502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07649928 ↗ |
| Modality | Protein / enzyme biologic | “Bispecific soluble HLA-DP restricted RASG12V specific T-cell receptor fused to anti-CD3 with Fc” NCT07649928 ↗ |